Naimish Patel

Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

Claus Bachert, Joseph K. Han, Martin Desrosiers et al. · The Lancet · 2019 · 1.5K citations

Medicine, Immunology, Otolaryngology +10

Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts

Surya P. Bhatt, Klaus F. Rabe, Nicola A. Hanania et al. · New England Journal of Medicine · 2023 · 458 citations · Full text

Veterinary Medicine, Immunology, Pharmacotherapy +17

Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis

Evan S. Dellon, Marc E. Rothenberg, Margaret H. Collins et al. · New England Journal of Medicine · 2022 · 456 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial

Michael Boyle, Scott C. Bell, Michael W. Konstan et al. · The Lancet Respiratory Medicine · 2014 · 442 citations

Pharmacy, Molecular Genetics, Pharmacotherapy +11

Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial

Amy S. Paller, Elaine C. Siegfried, Diamant Thaçi et al. · Journal of the American Academy of Dermatology · 2020 · 389 citations · Full text

Medicine, Dermatology, Pediatrics +14